Their lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI).
Their mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase the availability of care.
Vista Exclusive Content
It’s Time to Read “Vista’s View” Vista Partners Weekly Market Update 2-16-19 Now Available!
Vista Partners has published “Vista’s View” Vista Partners Weekly Market Update 2-16-19!” Each weekly newsletter is written by Vista Partners’ Managing Director, John Heerdink. Vista’s View includes an exclusive view on the stock market for the week, a “Stocks To Watch” section, featured stories that
Fertility Treatment Innovator INVO Bioscience Adds Michael J. Campbell as COO/VP of Business Development
Medford, MA-based INVO Bioscience (IVOB) is a medical device company focused on creating simplified treatments for patients diagnosed with infertility. Their solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients
“Global Expansion Slows” Vista Partners January 2019 Macro Economic and Investment Newsletter 1-30-19
Vista Partners (“Vista”) has published January 2019’s FREE Macroeconomic & Investment Monthly Newsletter, “Global Expansion Slows.” Vista’s monthly newsletter contains investment considerations for Banks, Biotech, Cloud Services, Energy, Fintech, Gold, Healthcare, Manufacturing, Mining, Natural Resources, Oil & Gas, Real Estate, Silver, and Technology. Vista Partners
INVOCELL IVF IS AN ENTIRELY NEW FDA APPROVED METHOD OF PERFORMING FERTILITY TREATMENTS FOR INFERTILE COUPLES WHICH IS MORE NATURAL, SIMPLER AND COSTS 50% LESS THAN CONVENTIONAL IVF TREATMENT.
Company News Around The Web
4 February 2019 | 2:01 pm
INVO Bioscience Appoints Michael J. Campbell as...
MEDFORD, Mass. , Feb. 4, 2019 /PRNewswire/ -- INVO Bioscien...
30 January 2019 | 2:15 pm
Vista Partners January 2019 Monthly Macroeconomic and...
SAN FRANSICO, CA / ACCESSWIRE / January 30, 2019 / Vista Par...
14 January 2019 | 1:00 pm
INVO Bioscience Closes Exclusive U.S. Licensing Agreement...
MEDFORD, Mass., Jan. 14, 2019 /PRNewswire/ -- INVO Bioscienc...
29 November 2018 | 2:01 pm
INVO Bioscience to Present at the LD...
MEDFORD, Mass., Nov. 29, 2018 /PRNewswire/ -- INVO Bioscien...
27 November 2018 | 2:01 pm
Fertility Partnership of St. Louis Expands Reproductive...
MEDFORD, Mass., Nov. 27, 2018 /PRNewswire/ -- INVO Bioscienc...
16 November 2018 | 2:01 pm
The Fertility Wellness Institute Becomes First Center...
MEDFORD, Mass., Nov. 16, 2018 /PRNewswire/ -- INVO Bioscien...
|Day Low - High|
|Year Low - High|